Temozolomide

In the US, Temozolomide (temozolomide systemic) is a member of the drug class alkylating agents and is used to treat Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma Multiforme, Melanoma and Melanoma - Metastatic.

US matches:

• Temozolomide


• Temozolomide Intravenous

UK matches:

• Temozolomide Hospira 100 mg hard capsules. (SPC)
• Temozolomide Hospira 140 mg hard capsules. (SPC)
• Temozolomide Hospira 180 mg hard capsules. (SPC)
• Temozolomide Hospira 20 mg hard capsules. (SPC)
• Temozolomide Hospira 250 mg hard capsules. (SPC)
• Temozolomide Hospira 5 mg hard capsules. (SPC)

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01AX03

CAS registry number (Chemical Abstracts Service)

0085622-93-1

Chemical Formula

C6-H6-N6-O2

Molecular Weight

194

Therapeutic Category

Antineoplastic agent, alkylating agent

Chemical Name

Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-

Foreign Names

• Temozolomidum (Latin)
• Temozolomid (German)
• Témozolomide (French)
• Temozolomida (Spanish)

Generic Names

• Temozolomide (OS: USAN, BAN)
• Témozolomide (OS: DCF)
• BRN 5547136 (IS)
• CCRG 81045 (IS: Cancer Research C.T.)
• M & B 39831 (IS: MayBaker)
• Methazolastone (IS)
• NSC 362856 (IS)
• SCH 52365 (IS: ScheringPlough)

Brand Names

• Dralitem
  Raffo, Argentina



• Temodal
  Bayer Schering, Iran; Essex, Germany; Essex Chemie, Switzerland; Kirby, Ecuador; Orion, Bulgaria; Schering, United Arab Emirates; Schering, Brazil; Schering, Egypt; Schering, Georgia; Schering, Iraq; Schering, Jordan; Schering, Kuwait; Schering, Lebanon; Schering, Qatar; Schering, Saudi Arabia; Schering, Yemen; Schering-Plough, Argentina; Schering-Plough, Australia; Schering-Plough, Belgium; Schering-Plough, Bulgaria; Schering-Plough, Bahrain; Schering-Plough, Canada; Schering-Plough, Chile; Schering-Plough, Colombia; Schering-Plough, Costa Rica; Schering-Plough, Czech Republic; Schering-Plough, Dominican Republic; Schering-Plough, Spain; Schering-Plough, Finland; Schering-Plough, France; Schering-Plough, United Kingdom; Schering-Plough, Greece; Schering-Plough, Guatemala; Schering-Plough, Hong Kong; Schering-Plough, Honduras; Schering-Plough, Croatia (Hrvatska); Schering-Plough, Hungary; Schering-Plough, Indonesia; Schering-Plough, Ireland; Schering-Plough, Israel; Schering-Plough, Iceland; Schering-Plough, Japan; Schering-Plough, Luxembourg; Schering-Plough, Mexico; Schering-Plough, Malaysia; Schering-Plough, Nicaragua; Schering-Plough, Netherlands; Schering-Plough, Norway; Schering-Plough, New Zealand; Schering-Plough, Oman; Schering-Plough, Panama; Schering-Plough, Peru; Schering-Plough, Philippines; Schering-Plough, Poland; Schering-Plough, Romania; Schering-Plough, Serbia; Schering-Plough, Russian Federation; Schering-Plough, Sweden; Schering-Plough, Singapore; Schering-Plough, Slovenia; Schering-Plough, Slovakia; Schering-Plough, El Salvador; Schering-Plough, Syria; Schering-Plough, Thailand; Schering-Plough, Turkey; Schering-Plough, Taiwan; Schering-Plough, Venezuela; Schering-Plough, South Africa; SP Europe, Austria; SP Europe, Denmark; SP Europe-B, Italy



• Temodar
  Schering, United States



• Temomedac
  Medac, Germany



• Temozolomid Hexal
  Hexal, Germany



• Temozolomid Hospira
  Hospira, Germany



• Temozolomide
  Teva USA, United States

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
SPC	Summary of Product Characteristics (UK)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.